Home - Products - Others - Other Targets - 4-methyl-6-phenyl-2H-pyranone

4-methyl-6-phenyl-2H-pyranone

CAS No. 4467-30-5

4-methyl-6-phenyl-2H-pyranone( 4-methyl-6-phenyl-2H-pyranone )

Catalog No. M29252 CAS No. 4467-30-5

4-methyl-6-phenyl-2H-pyranone is derived from Scutellaria baicalensis Georgi and improves mitochondrial functionality to protect astrocytes against hydrogen peroxide-induced toxicity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 45 Get Quote
10MG 63 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    4-methyl-6-phenyl-2H-pyranone
  • Note
    Research use only, not for human use.
  • Brief Description
    4-methyl-6-phenyl-2H-pyranone is derived from Scutellaria baicalensis Georgi and improves mitochondrial functionality to protect astrocytes against hydrogen peroxide-induced toxicity.
  • Description
    4-methyl-6-phenyl-2H-pyranone is derived from Scutellaria baicalensis Georgi and improves mitochondrial functionality to protect astrocytes against hydrogen peroxide-induced toxicity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    4-methyl-6-phenyl-2H-pyranone
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    4467-30-5
  • Formula Weight
    186.21
  • Molecular Formula
    C12H10O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cc1cc(oc(=O)c1)-c1ccccc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • AER-271

    AER-271 (AER271) is a selective, small molecule inhibitor of aquaporin-4 (AQP4), the prodrug of AER-270 with enhanced solubility.

  • Examorelin

    Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?

  • Gastrin I (1-14), hu...

    Gastrin I (1-14), human TFA is 1-14 fragment of human gastrin I peptide.